Novel esters of phenylalkanoic acid

Abstract: The esters of phenylalkanoic acid of the formula: wherein R¹ is 4-10 membered, saturated or unsaturated, mono- or bi-cyclic hetero ring containing as hetero atoms: (i) one or two nitrogen, (ii) two or three of nitrogen and sulfur in total, or (iii) one or two sulfur; R² is hydrogen; or R¹ and R², taken together with a nitrogen to which they are attached, form 4-7 membered, saturated or unsaturated, mono-­ cyclic hetero ring containing as hetero atoms: (i) one or two nitrogen, or (ii) two or three of nitrogen and oxygen in total, the aforementioned hetero rings, represented by R¹ or formed by R¹ and R², taken together with a nitrogen to which they are attached, may be substituted by one substituent selected from C1-4 alkyl and C2-5 acyl; R³ each, independently, is hydrogen or C1-4 alkyl; R⁴ is hydrogen, halogen, trihalomethyl, C1-4 alkyl, C1-4 alkoxyl C2-5 acyl, cyano, nitro or nitroxy; R⁵ each, independently, is hydrogen, C1-4 alkyl or phenyl; or the two R⁵'s, taken together with a carbon to which they are attached, form cyclopentane or cyclohexane; and the pharmaceutically acceptable acid addition salts thereof, have β₁-adrenergic receptor blocking activity, and therefore, are useful for the prevention of and/or in the treatment of cardiovascular diseases such as angina pectoris, myocardial infarction, congestive heart failure, hypertension, arrhythmia, etc.

Description: Field of the Invention The present invention relates to a ester of phenylalkanoic acid. More particularly, this invention relates to: i) The ester of phenylalkanoic acid of the following formula: and the pharmaceutically acceptable acid addition salts thereof, which have β₁-adrenergic receptor blocking activity, ii) processes for the preparation thereof, and iii) β₁-adrenergic receptor blocking agents containing them. Background of the Invention On the surface of cellular tissue responding to the stimulation of sympathetic nerve, the adrenergic receptor exists. This receptor is divided into two types, i.e. α and β. The reaction via α-receptor is generally excitation, and causes the contraction of a smooth muscle and vessel. On the other hand, the response of heart caused by the stimulation of β₁-receptor is the excitation such as the increase of heart rate, contraction and automaticity. The stimulation of β₂-receptor causes the relaxation of smooth muscle, e.g. tracheal, intestinal, uterine smooth muscle, etc. and the dilation of vessel. Accordingly, the selective blockade of β₁-receptor acts on the heart depressedly, and gives physiological changes, for example, the decrease of heart rate, contraction, automaticity and stroke volume. Such pharmacological properties show that β₁-receptor blockers are useful for the treatment of diseases which need the utmost decrease of myocardial oxygen demand, i.e. angina pectoris, myocardial infarction, congestive heart failure, hypertension arrhythmia, etc. Related Arts Up until now, the various β₁-blocking agents have been developed in order to accomplish the purpose described hereinbefore. Most of these agents have 3-aryloxy-2-hydroxypropylamine as the basic skeleton, and some of them have been already produced commercially. Recently, the derivatives having a high selectivity for β₁-receptor and having a short duration, have been energetically developed. The reason is because the conventional β₁-blockers block β₂-receptor slightly, as well as block β₁-receptor, and therefore induce occasionally the increase of broncho-resistance and thus bronchial asthma. The short-acting blockers are characterized by the ability to easily control the effect of the treatment. For example, the administration of β₁-blocker to a patient in acute myocardial infarction induces the decrease in myocardial oxygen demand and the prevention of the magnification of infarct area, and therefore is very useful. However, if β₁-blocking effect should continue after recovering the symptom, the function of heart would be excessively inhibited and his life would be endangered. In such case, it is desirable to remove the β₁-blocking effect soon. For example, there are known some short-acting derivatives having highly selective β₁-receptor blocking activity, as follows. (1) in the specification of the European Patent Publication No. 41491, the compounds of the formula: wherein R 1a is a group selected from isopropyl and tert -butyl; R 2a and R 3a , independently, are hydrogen; R 5a is a group selected from hydrogen, halogen, lower alkyl, lower alkenyl and lower alkoxy; R 4a is a group selected from alkyl, alkoxyalkyl, cycloalkyl, phenyl, arylalkyl and hydroxyalkyl; and na is 1 or 2, are disclosed, and (2) in the specification of the European Patent Publication No. 93155, the compounds of the formula: wherein R 1b is lower alkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, lower alkylcarboxymethyl, arylcarboxymethyl, aryl or aralkyl; A b is bond, lower alkylene or lower alkenylene; X b is 1 or 2, with the proviso that when X b is more than 1, each of may be the same or different; A rb is a heterocyclic ring, unsubstituted aromatic ring, or aromatic ring substituted by lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, halogen, acetoamido, amino, nitro, lower alkylamino, hydroxy, lower hydroxyalkyl or cyano; W b is C1-10 alkylene; B b is -NR 2b COR 3b , -NR 2b CONR 3b R 4b , -NR 2b SO₂R 3b , -NR 2b SO₂NR 3b R 4b or -NR 2b COOR 5b ; R 2b , R 3b , R 4b and R 5b are independently hydrogen, alkyl, alkoxyalkyl, alkoxyaryl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl or aralkyl, with the proviso that when B b is -NR 2b SO₂R 3b or -NR 2b COOR 5b , R 3b and R 5b are not hydrogen and that R 3b and R 4b , taken together with a nitrogen, may form a 5-7 membered hetero ring, are disclosed. Purpose of the Invention However, it is difficult to say that the compounds of the formulae (A) and (B) aforementioned are adequate for a practical use at the points of (1) blocking effect on β₁-receptor, (2) selectivity for β₁-receptor and (3) short-duration. Accordingly, the purpose of the present invention is to provide an ideal β₁-blocker fully satisfying the terms (1) to (3) aforementioned. The present inventors paid attention to the compounds of the formula (B) aforementioned and have found that the purpose is accomplished by replacing the ester moiety (R 1b ) in the formula (B) by an oxygen-containing heterocyclic ring. The esterification by an oxygen-containing heterocyclic ring has never been carried out before in the art, and further it is quite unexpected that the duration of β₁-blocking activity of the compound of formula (B) grows short by introducing such esters. The compound of the present invention of the formula (I) may be converted into the corresponding acid addition salts by known methods. Preferably, acid addition salts are pharmaceutically acceptable non-toxic salts and water-soluble. Suitable acid addition salts are, for example, an inorganic acid addition salt such as hydrochloride, hydrobromide, sulfate, phosphate, nitrate, or an organic acid addition salt such as acetate, lactate, tartarate, oxalate, fumarate, maleate, citrate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, gluconate. The compound of the present invention of the formula (I) may be prepared by subjecting to the epoxide-cleaving reaction of a compound of the formula: with a compound of the formula: The epoxide-cleaving reaction is well known per se and may be carried out in an inert organic solvent (diethyl ether, ethanol, isopropyl alcohol, tetrahydrofuran (THF), acetonitrile, N,N'-dimethylformamide (DMF), etc.), at a temperature from ambient to 50°C. The compound of the formula (II) may be prepared, for example, by subjecting to a series of reactions depicted in the following Scheme (A). wherein X is halogen, tosyloxy or mesyloxy. The compounds of the formula (III) may be prepared by subjecting to a reaction depicted in the following Scheme (B). The starting materials and each reagent used for the preparation in the present invention are known per se , or may be prepared easily by the known methods per se . For example, 3-(4-hydroxyphenyl)propionic acid is on the market. In each reaction in the present specification, products may be purified by conventional manner. For example, it may be carried out by distillation at atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization. Purification may be carried out after each reaction, or after a series of reactions. Pharmacological effect The β₁-receptor blocking effect of the compounds of the present invention has been confirmed by the following screening system. β-blocking activity of the compounds of the present invention in vivo Methods: Dogs were anesthetized with sodium barbital (300 mg/kg, ip). A femoral artery and both femoral veins were cannulated. Blood pressure was measured with a pressure transducer. Heart rate was measured from the blood pressure signal using a cardiotachometer. The β-blocking activity was assessed by the inhibition of isoproterenol-induced tachycardia. Isoproterenol was administered intravenously (0.1 ∼ 0.3 µg/kg) at 10 minutes intervals. When a regular tachycardia induced by isoproterenol was given, the compound of the present invention was administered (10 µg/kg/min, iv infusion) for 30 minutes. Isoproterenol was given repeatedly during and following infusion of a test compound. The inhibitory effects of the compounds of the present invention on tachycardia were calculated. The results were shown in the following Table I. Inhibition (%) = ((ΔRO - ΔRa) /ΔRO) X 100 ΔRO: the increment of heart rate by isoproterenol before infusion of the compound of the present invention ΔRa: the increment of heart rate by isoproterenol during and after infusion of the compound of the present invention Cardio selectivity of β-receptor blocking effect of the compounds of the present invention in vitro Methods: Heart and trachea were removed from the stunned guinea pig rapidly, and mounted in Krebs-Henseleit solution (referred to as "Krebs solution" hereafter) cooled with ice. Right atria was removed from the heart and connected to a force transducer adjusting the resting tension to 0.5 g in Krebs solution at 37°C (The solution was airated with 5% CO₂ and 95% O₂). Trachea was cut into zigzag strip and connected to a force transducer adjusting the resting tension to 0.5 g in the same manner as the atria. After one hour stabilization, the compound of the present invention or a vehicle was added. After one hour, isoproterenol (10⁻¹⁰ M to 10⁻⁴ M) was added cumulatively. Concentration-response curves to isoproterenol were then obtained. All response were calculated as percent of maximum increase in heart rate (in right atria) or percent of maximum decrease in tension (in trachea). The pA₂ values and the cardio selectivity of the compounds of the present invention were calculated. The results were shown in the following Table II. Example No. pA₂ value Cardio selectivity K B (trachea)/K B (right atria) right atria trachea 2(a) 6.59 4.18 255 Consideration: As shown in Table I and II aforementioned, it is understood that the compounds of the present invention of the formula (I) have a short-acting blocking effect selective for β₁-receptor. On the other hand, it was confirmed that the toxicity of the compounds of the present invention was very low. For example, the acute toxicity (LD₅₀) of the compound in Example 2(a) is 290 mg/kg in intravenous administration in mice. Therefore, the compounds of the present invention may be considered to be sufficiently safe and suitable for pharmaceutical use. As can be seen from the results of pharmacological experiments aforementioned, the compounds of the present invention of formula (I) have a short-acting blocking effect selective for β₁-receptor, and therefore are useful for the prevention of and/or in the treatment of cardiovascular diseases, for example, angina pectoris, myocardial infarction, congestive heart failure, hypertension, arrhythmia, etc. in mammals including human beings, especially human beings. For the purpose above described, the compounds of the present invention of the formula (I), and the pharmaceutically acceptable acid addition salts thereof may be normally administered systemically or partially, usually by oral or parenteral administration, preferably parenteral administration. The doses to be administered are determined depending upon age, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment, etc. In the human adult, the doses per hour per kg body weight are generally between 0.001 mg and 100 mg by intravenous infusion, preferably between 0.1 mg and 10 mg, and the doses per kg body weight per dose are generally between 0.001 mg and 10 mg by intravenous administration (one shot), preferably between 0.01 mg and 1 mg. As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than the ranges specified above and doses greater than the ranges specified above, may be used. In administration of the compounds of the present invention, solid compositions, liquid compositions and other compositions are used for oral administration, and injections, medicines for external use and suppositories are used for parenteral administration. Preferably, injections are used for the administration of the compounds of the present invention. Injections for parenteral administration include sterile aqueous or non-aqueous solution, suspensions and emulsions. In such injections, one or more of active compounds are admixed with at least one of inert aqueous diluents (distilled water for injection, physiological salt solution etc.) or inert non-aqueous diluents (propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSOLBATE 80 (registered trade mark) etc.). Injections may comprise the addition of other than inert diluents, e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agents (lactose etc.), assisting agents such as assisting agents for dissolving (glutamic acid, aspertic acid etc.). They may be usually sterilized by filtration (through a bacteria-retaining filter etc.), incorporation of sterilizing agents in the compositions or by irradiation. After sterilizing as described, they also be manufactured in the form of sterile solid compositions, for example, by freeze-drying, and which can be dissolved in sterile water or some other sterile diluents for injection immediately before used. Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules. Capsules includes both hard capsules and soft capsules. Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs, and may contain inert diluents commonly used in the art, such as distilled water or ethanol, etc. Other compositions for parenteral administration include liquids for external use, and endermic agent, such as ointments, liniment, suppositories for rectal administration, and pessaries which comprise one or more of the active compounds and may be prepared by known methods. Reference Examples and Examples The following Reference Examples and Examples illustrate the present invention. The solvents in the parentheses show the eluting or developing solvents and the ratios of the solvents used are by volume in chromatographic separation. Unless otherwise specified, "IR" were measured by KBr method. Reference Example 1 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-(4-hydroxyphenyl)-propionate Potassium carbonate (3.8 g) and potassium iodide (7.0 g) were added to a solution of 3-(4-hydroxyphenyl)propionic acid (7.00 g) in dimethyl sulfoxide (25 ml), and the mixture was stirred for 30 minutes at 100°C under an atmosphere of argon. (2,2-dimethyl-1,3-dioxolan-4-yl)methyl chloride (prepared by the method as described hereinafter; 19.04 g) was added to the mixture, and the mixture was stirred for 15 hours at the same temperature. The reaction mixture was poured into water (150 ml) and extracted with diethyl ether (150 ml x 2). The extract was washed with successive, a saturated aqueous solution of sodium bicarbonate, water and a saturated aqueous solution of sodium chloride, dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (n-hexane : ethyl acetate = 2 : 1) to give the title compound (6.69 g) as white solid having the following physical data. TLC (n-hexane : ethyl acetate = 1 : 1) : Rf = 0.54. (2,2-dimethyl-1,3-dioxolan-4-yl)methyl chloride used in the above reaction, was prepared by the following method. 3-chloro-1,2-propanediol (50 g) was dissolved in methylene chloride (100 ml) which was dried over molecular-sieves 3A, and p-toluenesulfonic acid (1.72 g) which was dried by heating, was added to the solution. The mixture was allowed to cool to 0°C on ice-bath with stirring under an atmosphere of argon, and 2-methoxypropene (56.2 ml) was added dropwise into the solution over 20 minutes. The reaction mixture was stirred for one hour at room temperature. Triethylamine (2.5 ml) was added dropwise to the reaction solution, and the mixture was concentrated under reduced pressure. The residue was extracted with the mixture of n-hexane and ethyl acetate (10 : 1), and the extract was washed with successive, water and a saturated aqueous solution of sodium chloride, dried over magnesium sulfate and concentrated under reduced pressure. The residue was distilled to give (2,2-dimethyl-1,3-dioxolan-4-yl)methyl chloride (52.38 g) having the following physical data. boiling point : 156 - 158°C; TLC (n-hexane : ethyl acetate = 1 : 1) : Rf = 0.88. Reference Example 2 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-[4-(2,3-epoxypropoxy)phenyl]propionate Potassium carbonate (1.406 g) and epibromohydrin (0.58 ml) were added to a solution of the phenol compound (prepared in Reference Example 1; 950 mg) in acetone (15 ml), and the mixture was refluxed with stirring for 16 hours. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in water (50 ml), and extracted with ethyl acetate. The extract was washed with succesive, water and a saturated aqueous solution of sodium chloride, dried over magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (ethyl acetate : methylene chloride = 4 : 96) to give the title compound (869 mg) as white solid having the following physical data. TLC (ethyl acetate : methylene chloride = 5 : 95) : Rf 0.55. Reference Example 3 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-[4-[2-hydroxy-3-(2-morpholinocarbonylaminoethyl)aminopropoxy]phenyl]propionate 2-(morpholinocarbonylamino)ethylamine (prepared by the method as described hereinafter; 216 mg) was added to a solution of the epoxide compound (prepared in Reference Example 2; 300 mg) in isopropanol (2 ml). Under an atmosphere of argon, the mixture was stirred for 16 hours at 30°C. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography on silica gel (ethyl acetate : methanol = 4 : 1) to give the title compound (197 mg) as pale yellow oil having the following physical data. TLC (methanol) : Rf 0.32. MS : m/z 509(M⁺), 407, 368, 309, 291, 244, 143, 125, 117, 101. 2-(morpholinocarbonylamino)ethylamine used in the above reaction, was prepared by the following method. N,N'-carbonyldiimidazole (1.489 g) was dissolved in dry chloroform (8 ml, distilled after the dehydration with calcium hydride), and a solution of morpholine (800 mg) in dry chloroform (2 ml) was added dropwise into the solution with stirring. The mixture was stirred for 30 minutes at room temperature, and ethylenediamine (2.45 ml) was added dropwise into the reaction solution, and further the mixture was stirred for two days at room temperature. The reaction mixture was concentrated under reduced pressure, and the residue was purified by column chromatography on silica gel (methanol) to give the title compound (1.49 g) as white solid having the following physical data. TLC (diethyl ether : ethanol = 1 : 1) : Rf 0.11. Example 1 The compounds of the present invention shown in the following Table III were obtained by the same procedure as Reference Example 3, by using the optically active epoxide compounds prepared by the same procedure as Reference Example 1 and 2. Reference Example 4 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-[4-[2-hydroxy-3-(2-morpholinocarbonylaminoethyl)aminopropoxy]phenyl]propionate 1/2 oxalate A solution of the amine compound (prepared in Reference Example 3, 197 mg) in chloroform (one ml) was added dropwise to a solution of oxalic acid in diethyl ether (0.1N, 3.87 ml) with stirring, and then the solvent was evaporated away. The obtained solid was dried under reduced presure overnight to give the title compound (190 mg) as pale orange crystal having the following physical data. MS : m/z 422, 407, 346, 329, 309, 291, 244, 143, 125, 99; IR : ν 3352, 2954, 2857, 1734, 1616, 1542, 1514, 1438, 1307, 1259, 1119, 1044, 827, 768, 721. Example 2 (a) - (c) The compounds of the present invention shown in the following Table IV were obtained by the same procedure as Reference Example 4, by using the compounds prepared in Example 1 and the various acids. Formulation Example The following components were admixed in conventional manner. The solution obtained was sterilized in conventional manner, placed in 2 ml portions, in ampoules, and freeze-dried to obtain 100 ampoules each containing 100 ml of the active ingredient for use as intravenous infusion.  (2,2-dimethyl-1,3-dioxolan-4S-yl)methyl 3-[4-[2S-hydroxy-3-(2-morpholinocarbonylaminoethyl)aminopropoxy]-phenyl]propionate 1/2 oxalate 10 g  maltose 20 g  distilled water for injection 200 ml

Claims: Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE An ester of phenylalkanoic acid of the formula: or the pharmaceutically acceptable acid addition salts thereof. A process for the preparation of an ester of phenylalkanoic acid of the formula: or the pharmaceutically acceptable acid addition salts thereof, which comprises: (i) subjecting to the epoxide-cleaving reaction of a compound of the formula: with a compound of the formula: and (ii) converting an ester of phenylalkanoic acid of the formula (I) into the corresponding acid addition salts by known methods, if necessary. A pharmaceutical composition which comprises, as active ingredient, an ester of phenylalkanoic acid of the formula (I) depicted in claim 1) or the pharmaceutically acceptable acid addition salt thereof, with a pharmaceutical carrier or coating. An ester of phenylalkanoic acid of the formula (I) depicted in claim 1) or the pharmaceutically acceptable acid addition salts thereof, for use as preventing and treating agents of cardiovascular diseases such as angina pectoris, myocardial infarction, congestive heart failure, hypertension, arrhythmia. Claims for the following Contracting States : ES, GR A process for the preparation of an ester of phenylalkanoic acid of the formula: or the pharmaceutically acceptable acid addition salts thereof, which comprises: (i) subjecting to the epoxide-cleaving reaction of a compound of the formula: with a compound of the formula: and (ii) converting an ester of phenylalkanoic acid of the formula (I) into the corresponding acid addition salts by known methods, if necessary. A process for the preparation of a pharmaceutical composition which comprises, as active ingredient, an ester of phenylalkanoic acid of the formula (I) depicted in claim 1 or the pharmaceutically acceptable acid addition salt thereof, with a pharmaceutical carrier or coating. A process for the preparation of an ester of phenylalkanoic acid of the formula (I) depicted in claim 1 or the pharmaceutically acceptable acid addition salts thereof, for use as preventing and treating agents of cardiovascular diseases such as angina pectoris, myocardial infarction, congestive heart failure, hypertension, arrhythmia.

Inventors: IGUCHI SADAHIKO C O MINASE RES, KAWAMURA MASANORI C O MINASE R, MIYAMOTO TSUMORU C O MINASE RE, IGUCHI, SADAHIKO, C/O MINASE RESEARCH INSTITUTE, KAWAMURA, MASANORI, C/O MINASE RESEARCH INSTITUTE, MIYAMOTO, TSUMORU, C/O MINASE RESEARCH INSTITUTE
Applicants: ONO PHARMACEUTICAL CO, ONO PHARMACEUTICAL CO., LTD.
Application year: 1990
Main classification: C07D405
IPC codes: A61P9, C07D405, A61K31, C07D317